JP2021531276A5 - - Google Patents
Info
- Publication number
- JP2021531276A5 JP2021531276A5 JP2021502545A JP2021502545A JP2021531276A5 JP 2021531276 A5 JP2021531276 A5 JP 2021531276A5 JP 2021502545 A JP2021502545 A JP 2021502545A JP 2021502545 A JP2021502545 A JP 2021502545A JP 2021531276 A5 JP2021531276 A5 JP 2021531276A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- idua
- expression vector
- immunosuppressive therapy
- subject
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024040767A JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699923P | 2018-07-18 | 2018-07-18 | |
| US62/699,923 | 2018-07-18 | ||
| PCT/US2019/042205 WO2020018665A1 (en) | 2018-07-18 | 2019-07-17 | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024040767A Division JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531276A JP2021531276A (ja) | 2021-11-18 |
| JP2021531276A5 true JP2021531276A5 (https=) | 2022-07-26 |
| JPWO2020018665A5 JPWO2020018665A5 (https=) | 2022-07-26 |
Family
ID=69164759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502545A Pending JP2021531276A (ja) | 2018-07-18 | 2019-07-17 | 完全ヒトグリコシル化ヒトα−Ｌ−イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
| JP2024040767A Pending JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024040767A Pending JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210275647A1 (https=) |
| EP (1) | EP3823590A4 (https=) |
| JP (2) | JP2021531276A (https=) |
| KR (1) | KR20210034037A (https=) |
| AU (1) | AU2019306236A1 (https=) |
| BR (1) | BR112021000830A2 (https=) |
| CA (1) | CA3106651A1 (https=) |
| IL (1) | IL280198B2 (https=) |
| SG (1) | SG11202100423YA (https=) |
| WO (1) | WO2020018665A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50016A (fr) | 2017-07-06 | 2020-07-08 | Univ Pennsylvania | Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| US20190114858A1 (en) * | 2017-10-16 | 2019-04-18 | Raritan Americas, Inc. | System for controlling access to an equipment rack and intelligent power distribution unit and control unit used therein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001097829A2 (en) * | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7560425B2 (en) * | 2002-06-07 | 2009-07-14 | Waratah Pharmaceuticals Inc. | Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes |
| EP2052083B1 (en) * | 2006-09-21 | 2014-01-08 | The Scripps Research Institute | Genetically programmed expression of selectively sulfated proteins in eubacteria |
| EP3230438B1 (en) * | 2014-12-12 | 2024-12-04 | University of Copenhagen | N-glycosylation |
| HK1256341A1 (zh) * | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| EP3411488A1 (en) * | 2016-02-03 | 2018-12-12 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| PL3411484T3 (pl) * | 2016-02-05 | 2024-02-19 | Emory University | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
| EP3541946A1 (en) * | 2016-11-15 | 2019-09-25 | Regents Of The University Of Minnesota | Method for improving neurological function in mpsi and mpsii and other neurological disorders |
| CA3049915A1 (en) * | 2017-01-31 | 2018-08-09 | Stephen YOO | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) |
-
2019
- 2019-07-16 IL IL280198A patent/IL280198B2/en unknown
- 2019-07-17 JP JP2021502545A patent/JP2021531276A/ja active Pending
- 2019-07-17 KR KR1020217004709A patent/KR20210034037A/ko active Pending
- 2019-07-17 EP EP19837268.2A patent/EP3823590A4/en active Pending
- 2019-07-17 WO PCT/US2019/042205 patent/WO2020018665A1/en not_active Ceased
- 2019-07-17 CA CA3106651A patent/CA3106651A1/en active Pending
- 2019-07-17 US US17/260,732 patent/US20210275647A1/en active Pending
- 2019-07-17 BR BR112021000830-6A patent/BR112021000830A2/pt not_active Application Discontinuation
- 2019-07-17 AU AU2019306236A patent/AU2019306236A1/en not_active Abandoned
- 2019-07-17 SG SG11202100423YA patent/SG11202100423YA/en unknown
-
2024
- 2024-03-15 JP JP2024040767A patent/JP2024095680A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508289A5 (https=) | ||
| US12274743B2 (en) | Nucleic acid vaccines | |
| JP2021531276A5 (https=) | ||
| JP6896050B2 (ja) | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 | |
| Matsushita et al. | Microglia activation precedes the anti-opioid BDNF and NMDA receptor mechanisms underlying morphine analgesic tolerance | |
| US20240307522A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| US11274158B2 (en) | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | |
| JP2017052783A5 (https=) | ||
| JP2019522989A (ja) | ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 | |
| US20150051137A1 (en) | Peptide and uses therefor | |
| AU2022233960A1 (en) | Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders | |
| US20200360364A1 (en) | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using chrna6 activators | |
| KR20210078428A (ko) | 중추신경계 통증신호 제어를 통한 암유발 통증 완화 방법 | |
| JPWO2020018665A5 (https=) | ||
| Xie et al. | Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies | |
| US20260035408A1 (en) | WKYMVm peptide analogues having six residues and uses thereof | |
| Crosson et al. | Heather Melichar | |
| WO2023201133A1 (en) | Cell therapy for alzheimer's disease | |
| Tayebati et al. | (Neuro) transmitter systems in circulating immune cells: a target of immunopharmacological interventions? | |
| Yang et al. | Progress in Mechanism of E. coli K1 Crossing the Blood-brain Barrier | |
| HK40072892A (en) | Nucleic acid vaccines | |
| CN119280206A (zh) | 精胺在制备抗抑郁药中的应用 | |
| van der Kleij et al. | Significance of Sensory Neuropeptides and the Immune Response | |
| US20220033490A1 (en) | Methods and compositions for treating cancer using chrna6 inhibitors |